The Patent Finder

Suzhou Novartis Technical Development Co., Ltd.

Also on record
Records under this name other than patents Suzhou Novartis Technical Development Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Suzhou Novartis Technical Development Co., Ltd.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,878,973Bicyclic Compounds and their Uses
conveyed to Novartis AG
In force
 · High confidence
In forceHigh confidence
US 12,679,8347-oxo-[1,2,4]triazolo[1,5-a]pyrimidin-4(7H)-yl) Compounds and Uses Thereof
conveyed to Novartis AG
In force
 · High confidence
In forceHigh confidence
US 12,441,737Manufacture of Compounds and Compositions for Inhibiting the Activity of SHP2
conveyed to Novartis AG
In force
 · High confidence
In forceHigh confidence
US 12,084,442Naphthyridinone Derivatives for the Treatment of a Disease or Disorder
now held by Novartis AG
In force
 · High confidence
In forceHigh confidence
US 12,774,275Compounds and Compositions for the Treatment of Coronaviral Related Diseases
conveyed to Novartis AG
In force
 · High confidence
In forceHigh confidence
US 12,378,222NLRP3 Inflammasome Inhibitors
now held by Novartis AG
In force
 · High confidence
In forceHigh confidence
18/002,291Process for the Manufacture of 1,4-Disubstituted Pyridazine Compounds
conveyed to Novartis AG
Abandoned
Abandoned May 14, 2024
AbandonedAbandoned May 14, 2024
18/250,466New Crystalline Forms of a Kras G12C Inhibitor Compound
conveyed to Novartis AG
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/281,732Fatty Acid-Bifunctional Degrader Conjugates and Their Methods of Use
conveyed to Novartis AG
Abandoned
Abandoned Nov 17, 2026
AbandonedAbandoned Nov 17, 2026
18/363,207NLRP3 Inflammasome Inhibitors
conveyed to Novartis AG
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
10 of 17 records shown.
Pro members see all 17.
Pro members: see all 17 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited